JAZZ PHARMACEUTICALS PLC news, videos and press releases
For more news please use our advanced search feature.
JAZZ PHARMACEUTICALS PLC - More news...
JAZZ PHARMACEUTICALS PLC - More news...
- Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
- Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting
- Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
- Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
- Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
- Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
- Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
- Jazz Pharmaceuticals Joins the Movement for Awareness and Support on World Cancer Day with The Upside Down Challenge
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals Announces CEO Succession Plan
- Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
- Celebrating International Volunteers Day: Honoring the Impact of Volunteerism and Community Engagement at Jazz Pharmaceuticals
- Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
- Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
- Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
- Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
- Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
- Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
- Jazz Pharmaceuticals Iberia Recognized as One of the 100 Best Companies To Work for in Spain
- Jazz Pharmaceuticals entre las 100 Mejores Empresas Para Trabajar en España este 2024
- Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
- Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
- Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
- Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Employee Well-Being: Fostering a Great Place To Work at Jazz Pharmaceuticals
- Shared Values, Shared Success, at Jazz Pharmaceuticals
